Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Unodil (alprostadil)
- Development stage
- Unknown
- Lead developer
- Zhejiang Sunshine Mandi Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Alprostadil is a synthetic variant of Prostaglandin E1 (PGE1) that acts as a potent vasodilator and inhibitor of platelet aggregation. Marketed by Sunshine Mandi Pharmaceutical (a subsidiary of 3SBio) under the brand name Unodil, this specific formulation is a liposomal injection designed to enhance drug stability and therapeutic efficacy by protecting the active ingredient from rapid metabolism in the lungs. It works by binding to prostaglandin E (EP) receptors, which activates adenylate cyclase and increases intracellular cAMP levels, leading to smooth muscle relaxation and vasodilation. It is primarily indicated for the treatment of chronic arterial occlusive diseases, such as thromboangiitis obliterans (Buerger's disease) and arteriosclerosis obliterans, and is used to improve microcirculation in patients with cardiovascular and cerebrovascular complications.
- Brand names
- Unodil乌诺地尔
- Other names
- prostaglandin E1PGE1PGE-1PGE 1
02
Targets
PTGER1 (Prostaglandin E Receptor 1)PTGER2 (Prostaglandin E2 receptor EP2)PTGER3 (Prostaglandin E2 receptor EP3 subtype)PTGER4 (Prostaglandin E2 receptor EP4 subtype)
Beyond the preview
Go deeper on Unodil (alprostadil).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Unodil (alprostadil).